Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer
作者: David GroheuxL. BiardJ. Lehmann-CheL. TeixeiraF. A. BouhidelB. PoirotP. BertheauP. MerletM. EspiéM. Resche-RigonC. SotiriouP. Cremoux
作者单位: 1Department of Nuclear Medicine, Saint-Louis Hospital
2University Paris-Diderot, Sorbonne Paris Cité
3Department of Biostatistics, Saint-Louis Hospital
4Molecular Oncology Unit, Saint-Louis Hospital
5Breast Diseases Unit, Saint-Louis Hospital
6Department of Pathology, Saint-Louis Hospital
7Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles
刊名: European Journal of Nuclear Medicine and Molecular Imaging, 2018, Vol.45 (8), pp.1279-1288
来源数据库: Springer Journal
DOI: 10.1007/s00259-018-3998-z
关键词: FDG-PET/CTGenomic grade indexTriple negative breast cancerNeoadjuvant chemotherapyPathological complete responseEvent free survival
英文摘要: Abstract(#br) Purpose(#br)Survival is increased when pathological complete response (pCR) is reached after neoadjuvant chemotherapy (NAC), especially in triple-negative breast cancer (TNBC) patients. Positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) and the genomic grade index (GGI), each separately, showed good potential to predict pCR. Our study was designed to evaluate the predictive value for the therapeutic response of a combination of parameters based on FDG-PET, histoclinical features and molecular markers of proliferation.(#br) Methods(#br)Molecular parameters were measured on pre-treatment biopsy. Tumor metabolic activity was measured using two PET/CT scans, one before and one after 2 cycles of NAC. The pCR was determined on specimen...
全文获取路径: Springer  (合作)